| Literature DB >> 35885043 |
Ioana Maria Carmen Ienașcu1,2, Adina Căta1, Mariana Nela Ştefănuț1, Iuliana Popescu3, Gerlinde Rusu4, Paula Sfîrloagă1, Daniel Ursu1, Cristina Moşoarcă1, Anamaria Dabici1, Corina Danciu5,6, Delia Muntean5,7,8, Raluca Pop5.
Abstract
The goal of this research was to design novel chloro-substituted salicylanilide derivatives and their β-cyclodextrin complexes in order to obtain efficient antibacterial compounds and to demonstrate the beneficial role of complexation on the efficiency of these compounds. Thus, salicylanilide derivatives, esters, and hydrazides were obtained by microwave-assisted synthesis and their structure proven based on FTIR and NMR spectra. In order to improve water solubility, chemical and physical stability, and drug distribution through biological membranes, the inclusion complexes of the ethyl esters in β-cyclodextrin were also obtained using kneading. Inclusion-complex characterization was accomplished by modern analytical methods, X-ray diffraction, SEM, TGA, FTIR, and UV-vis spectroscopy. The newly synthesized compounds were tested against some Gram-positive and Gram-negative bacteria. Antimicrobial tests revealed good activity on Gram-positive bacteria and no inhibition against Gram-negative strains. The MIC and MBC values for compounds derived from N-(2-chlorophenyl)-2-hydroxybenzamide were 0.125-1.0 mg/mL. N-(4-chlorophenyl)-2-hydroxybenzamide derivatives were found to be less active. The inclusion complexes generally behaved similarly to the guest compounds, and antibacterial activity was not been altered by complexation.Entities:
Keywords: antibacterial activity; inclusion complexes; salicylanilide derivatives
Year: 2022 PMID: 35885043 PMCID: PMC9312894 DOI: 10.3390/biomedicines10071740
Source DB: PubMed Journal: Biomedicines ISSN: 2227-9059
Scheme 1Synthetic pathway for salicylanilide derivatives.
Scheme 2The numbering of aromatic nuclei.
Scheme 3Structures of the two components of the ethyl ester–β-cyclodextrin complexes.
Figure 1XRD spectra of β-cyclodextrin, ethyl ester, inclusion complex, physical mixture: (a) ethyl 2-(2-((2-chlorophenyl)carbamoyl)phenoxy)acetate series; (b) ethyl 2-(2-((4-chlorophenyl) carbamoyl)phenoxy)acetate series.
Figure 2SEM images of β-cyclodextrin, ethyl ester, inclusion complex, physical mixture: (a) ethyl 2-(2-((2-chlorophenyl)carbamoyl)phenoxy)acetate series; (b) ethyl 2-(2-((4-chlorophenyl) carbamoyl)phenoxy)acetate series.
Figure 3FTIR spectra of β-cyclodextrin, ethyl ester, inclusion complex, physical mixture: (a) ethyl 2(2-((2-chlorophenyl)carbamoyl)phenoxy)acetate series; (b) ethyl 2-(2-((4-chlorophenyl) carbamoyl)phenoxy)acetate series.
Modified characteristic vibrations of ethyl esters after complexation.
| Characteristic | EE2 | EE4 | ||
|---|---|---|---|---|
| Free | Complexed | Free | Complexed | |
| Sk “1600” | 1592.14 | 1593.11 | 1593.11 | 1596.97 |
| γNH + νCN sec. amide | 1535.25 | 1536.21 | 1533.32 | 1535.25 |
| Sk “1500” | 1484.14, 1438.81 | 1482.21, 1439.78 | 1436.88 | 1440.74 |
| σCH3 aliphatic | 1391.56 | 1394.45 | 1392.52 | 1396.38 |
| σCH aromatic | 1378.06 | 1375.17 | 1361.66 | overlaped |
| νasCOC aliphatic | 1161.08 | 1156.26 | 1157.22 | 1155.29 |
Modified characteristic vibrations of β-cyclodextrin after complexation.
| β-Cyclodextrin | Free | Complexed EE2 | Complexed EE4 |
|---|---|---|---|
| ν[OH] | 3396.45 | 3395.48 | 3398.38 |
| ν[CH2] | 2925.84 | 2928.74 | 2925.84 |
| ν[C–C] | 1157.22 | 1156.26 | 1155.29 |
| ν[O–H] | 1028.96 | 1029.93 | 1033.79 |
Figure 4UV-vis spectra of β-cyclodextrin, ethyl ester, inclusion complex, physical mixture: (a) ethyl 2-(2-((2-chlorophenyl)carbamoyl)phenoxy)acetate series; (b) ethyl 2-(2-((4-chlorophenyl) carbamoyl)phenoxy)acetate series.
Figure 5TGA curves of β-cyclodextrin, ethyl ester, inclusion complex, physical mixture: (a) ethyl 2-(2-((2-chlorophenyl)carbamoyl)phenoxy)acetate series; (b) ethyl 2-(2-((4-chlorophenyl) carbamoyl)phenoxy)acetate series.
Antibacterial activity of test compounds.
| Microbial Strains | Test Compounds | MIC (mg/mL, *) | MBC (mg/mL, *) |
|---|---|---|---|
| EE2 | 0.25 | 0.25 | |
| EM2 | 0.25 | 0.25 | |
| HD2 | 0.5 | 0.5 | |
| CEE2 | 0.25 | 0.25 | |
| EE4 | NA | NA | |
| EM4 | 0.5 | 0.5 | |
| HD4 | 0.5 | 0.5 | |
| CEE4 | NA | NA | |
| EE2 | 0.125 | 0.125 | |
| EM2 | 0.125 | 0.125 | |
| HD2 | 0.25 | 0.5 | |
| CEE2 | 0.125 | 0.125 | |
| EE4 | 1.0 | 1.0 | |
| EM4 | 0.5 | 0.5 | |
| HD4 | 0.5 | 0.5 | |
| CEE4 | NA | NA | |
| EE2 | 0.5 | 0.5 | |
| EM2 | 0.5 | 0.5 | |
| HD2 | 1.0 | 1.0 | |
| CEE2 | 0.5 | 0.5 | |
| EE4 | 1.0 | 1.0 | |
| EM4 | 1.0 | 1.0 | |
| HD4 | 1.0 | 1.0 | |
| CEE4 | NA | NA | |
| EE2 | NA | NA | |
| EM2 | NA | NA | |
| HD2 | NA | NA | |
| CEE2 | NA | NA | |
| EE4 | NA | NA | |
| EM4 | NA | NA | |
| HD4 | NA | NA | |
| CEE4 | NA | NA | |
| EE2 | NA | NA | |
| EM2 | NA | NA | |
| HD2 | NA | NA | |
| CEE2 | NA | NA | |
| EE4 | NA | NA | |
| EM4 | NA | NA | |
| HD4 | NA | NA | |
| CEE4 | NA | NA |
* NA—compounds exhibited no activity at tested concentrations.